Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Brown

Sports Medicine Elkhorn, NE Medical Doctor

NPI 1801827431 CMS profile 1041054

222 N 192Nd St, Elkhorn, NE 68022

Open in the dashboard

General payments

$8,163

123 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephen Brown of Elkhorn, NE is reported in the CMS Open Payments database as having received $8,163 across 123 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,326 11
2024 General $811 12
2023 General $1,617 20
2022 General $886 24
2021 General $884 17
2020 General $1,014 11
2019 General $1,625 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Brown
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Stephen Brown were reported at $1,326. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Stephen Brown Sports Medicine median Middle half National median
2019 $1,625 $1,176 $199–$4,249 $163
2020 $1,014 $708 $96–$2,890 $114
2021 $884 $1,213 $152–$3,994 $132
2022 $886 $1,230 $159–$3,998 $149
2023 $1,617 $584 $146–$2,836 $160
2024 $811 $628 $163–$3,168 $164
2025 $1,326 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. DePuy Synthes Sales Inc. $2,561 28 payments
  2. Conetic Solutions, Inc. $1,694 16 payments
  3. Zimmer Biomet Holdings, Inc. $1,591 15 payments
  4. Stryker Corporation $569 9 payments
  5. Baxter Healthcare $287 4 payments
  6. Smith+Nephew, Inc. $284 7 payments
  7. Arthrex, Inc. $193 5 payments
  8. Pacira Pharmaceuticals Incorporated $142 3 payments
  9. Medtronic USA, Inc. $130 1 payment
  10. Sanara MedTech Inc. $107 1 payment
  11. Other $604 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,279 114 payments
  2. Travel and Lodging $2,142 8 payments
  3. Education $742 1 payment
Products named General payments · program years 2019–2025
  1. INHANCE $1,190 6 payments
  2. ATTUNE $789 6 payments
  3. Comprehensive Shoulder System $696 4 payments
  4. REUNION $291 2 payments
  5. FLOSEAL $180 3 payments
  6. AETOS Shoulder System $135 1 payment
  7. AQUAMANTYS $130 1 payment
  8. BIOLOX DELTA $125 1 payment
  9. ORTHOVISC $124 9 payments
  10. MONOVISC $124 9 payments
  11. Other $2,395 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

97

Median for Orthopedic Surgery: 203

Drug cost

$704

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 69 $421
Celecoxib Generic 14 $271
Cephalexin Generic 14 $12

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$167,317

Of which drugs: $34,229

Medicare patients

387

Average age 75

Services billed

19,693

237 women, 150 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Chronic kidney disease 30%
Diabetes 29%
Ischemic heart disease 21%
Depression 20%
Atrial fibrillation 19%
Heart failure 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 41 253 $23,149
Injection, methylprednisolone acetate, 1 mg J1010 Office 128 17,600 $1,771
Injection, methylprednisolone acetate, 80 mg J1040 Office 70 107 $595

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

123 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record